Keryx Biopharmaceuticals Inc (KERX.OQ)

KERX.OQ on NASDAQ Stock Exchange Capital Market

9.23USD
1 Aug 2013
Price Change (% chg)

$0.13 (+1.43%)
Prev Close
$9.10
Open
$9.20
Day's High
$9.28
Day's Low
$9.14
Volume
39,554
Avg. Vol
554,251
52-wk High
$9.98
52-wk Low
$1.68

KERX.OQ

Chart for KERX.OQ

About

Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase... (more)

Overall

Beta: 3.88
Market Cap (Mil.): $743.63
Shares Outstanding (Mil.): 81.72
Dividend: --
Yield (%): --

Financials

  KERX.OQ Industry Sector
P/E (TTM): -- 47.13 37.76
EPS (TTM): -0.25 -- --
ROI: -33.54 -2.58 18.76
ROE: -34.38 -2.66 19.59
Search Stocks

Competitors

  Price Change
Takeda Pharmaceutical Company Limited (4502.T) ¥4,580 +205.00
Astellas Pharma Inc (4503.T) ¥5,340 +90.00
Pfizer Inc. (PFE.N) $29.29 +0.06
Novartis AG (NOVN.VX) CHF66.60 +0.35
Merck & Co., Inc. (MRK.N) $48.34 +0.17
Bayer AG (BAYGn.DE) €89.64 +2.29
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.89 -3.28
Eli Lilly & Co. (LLY.N) $53.29 +0.18
Amgen, Inc. (AMGN.OQ) $108.86 +0.57

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$472.00
Provider: S&P Capital IQ Quantitative Report
$69.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks